Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

34.21
+0.53001.57%
Post-market: 34.330.1200+0.35%18:47 EDT
Volume:926.88K
Turnover:31.55M
Market Cap:2.03B
PE:-4.88
High:34.34
Open:33.60
Low:33.21
Close:33.68
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:1.11
T/O Rate:1.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.98
PE(LYR):-4.80

Loading ...

Agios Pharmaceuticals price target lowered to $41 from $44 at BofA

TIPRANKS
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), GeneDx Holdings (WGS) and Agios Pharma (AGIO)

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Agios Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 21

Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition

TIPRANKS
·
Apr 21

H.C. Wainwright cuts Agios target on smaller market post Novo data

TIPRANKS
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

Agios Pharmaceuticals falls -23.7%

TIPRANKS
·
Apr 20

Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. -- Barrons.com

Dow Jones
·
Apr 20

Agios sinks after Novo Nordisk reports sickle cell data

TIPRANKS
·
Apr 20

Agios could come under pressure off Novo Nordisk headline, says Truist

TIPRANKS
·
Apr 20

BUZZ-Agios falls after Novo's sickle cell disease drug shows promise in late-stage study

Reuters
·
Apr 20

Agios Pharma Shares Down 15.5% Premarket After Rival Novo Nordisk Reports Late-Stage Data for Sickle Cell Disease Drug

THOMSON REUTERS
·
Apr 20

Agios Pharma (AGIO) Receives a Buy from Bank of America Securities

TIPRANKS
·
Apr 08

What Agios Pharmaceuticals (AGIO)'s FDA-Backed Accelerated Path for Mitapivat in Sickle Cell Disease Means For Shareholders

Simply Wall St.
·
Apr 08

Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
Apr 07

Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan

TIPRANKS
·
Apr 06

Agios to report first-quarter results in conference call and webcast

Reuters
·
Apr 06

Agios Pharmaceuticals Inc : Leerink Partners Raises Target Price to $60 From $47

THOMSON REUTERS
·
Apr 02